Tango Therapeutics reports pancreatic cancer trial data

Tango Therapeutics (TNGX) reported Phase 1/2 trial data for vopimetostat in pancreatic and lung cancer. The study showed an 82% response rate in pancreatic cancer patients, with a 9-month progression-free survival rate of 88%. The combination was well-tolerated. Tango plans a Phase 3 trial in 2027. Vopimetostat is an investigational PRMT5 inhibitor.

Original reporting
Published Oct 23, 2026, 10:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 10:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$TNGX
Bullish
high confidence
Mentioned
$TNGX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TNGXBullishMed
01

Why it matters

The disclosed data could accelerate the timeline for a Phase 3 registrational trial and improve valuation.

02

Market read

First report of high‑response early‑stage data; likely to move the stock and influence related oncology peers.

03

What to watch

Potential competition from other KRAS‑targeted agents and the need for larger Phase 2/3 data.

Relevance 8/10Novelty 8/10Timing: today

Background

Tango Therapeutics is a clinical‑stage biotech focused on PRMT5 inhibition for oncology.

Company-level read

Ticker impact

$TNGXBullishHigh confidence
Context

Tango Therapeutics disclosed Phase 1/2 trial results showing an 82% objective response rate in MTAP‑deleted/RAS‑mutant pancreatic cancer patients.

Expected impact

likely upward pressure as the market prices in the promising response rates

Evidence & confidence

Phase data with high response rates and no dose‑limiting toxicities are rare and suggest a potential regulatory milestone.

Market effects

May lift sentiment for biotech firms developing PRMT5 inhibitors and other targeted oncology therapies.

Limited to U.S. and European biotech markets.

Modest, primarily affecting specialty oncology investors.

Counterpoint

Skeptics may question durability of response and lack of long‑term survival data.

Key entities

  • Tango Therapeutics Inc.

    Biotech developing vopimetostat and daraxonrasib combinations.

Related articles

$TNGXMedAI 8/10

Tango Therapeutics Reports Q3 2026 Net Loss of $68.4 Million

Tango Therapeutics reported a Q3 2026 net loss of $68.4M, up from a $15.9M profit a year earlier, due to higher expenses and zero collaboration revenue. Cash reserves totaled $977.5M. The company shared promising Phase 1/2 results for vopimetostat combined with daraxonrasib in pancreatic cancer, with an 82% response rate and 88% nine-month survival rate. Tango plans to initiate a Phase 3 trial in 2027 and focus on PRMT5-targeted therapies.

$TNGXMedAI 8/10

Tango Therapeutics 3Q 2026: Revenue $0, EPS ($0.39) — 10-Q Summary

Tango Therapeutics reported no revenue in 3Q 2026, down from $53.8M a year earlier, with a net loss of $68.39M. R&D and G&A expenses rose, partially offset by higher interest income. Clinical trials for vopimetostat combinations showed promising results. The company plans a global trial in 2027 and will focus on PRMT5 therapies, reducing its workforce by 14%.

$TNGXHighAI 9/10

Tango Therapeutics Reports Third Quarter 2026 Financial Results

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progre